Bluebird Bio Q3 2022 Earnings Report
Key Takeaways
Bluebird Bio's Q3 2022 saw the commercial launch of ZYNTEGLO, FDA approval of SKYSONA, and the appointment of a new CFO. The company is on track for its first apheresis in Q4 2022 and anticipates commercial readiness for SKYSONA in the same quarter. Financial guidance was adjusted to account for increased launch investments. The company ended the quarter with $186M in cash, cash equivalents, marketable securities, and restricted cash.
ZYNTEGLO commercial launch is underway and on track for first apheresis in Q4 2022.
SKYSONA received FDA approval and commercial readiness is expected in Q4 2022.
Chris Krawtschuk was appointed as the new Chief Financial Officer.
The company ended the quarter with $186 million in cash and cash equivalents, marketable securities, and restricted cash.
Bluebird Bio
Bluebird Bio
Forward Guidance
Bluebird Bio is adjusting its fourth quarter 2022 projected cash burn to between $75 million to $80 million.